Acrivon Therapeutics, Inc.
ACRV
$2.05
-$0.06-2.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.82M | 4.74M | 5.37M | 6.04M | 6.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.67M | 19.90M | 20.12M | 19.69M | 22.65M |
| Operating Income | -18.67M | -19.90M | -20.12M | -19.69M | -22.65M |
| Income Before Tax | -17.96M | -19.04M | -18.99M | -18.23M | -21.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.96M | -19.04M | -18.99M | -18.23M | -21.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.96M | -19.04M | -18.99M | -18.23M | -21.01M |
| EBIT | -18.67M | -19.90M | -20.12M | -19.69M | -22.65M |
| EBITDA | -18.26M | -19.52M | -19.76M | -19.34M | -22.31M |
| EPS Basic | -0.43 | -0.49 | -0.49 | -0.47 | -0.55 |
| Normalized Basic EPS | -0.27 | -0.31 | -0.31 | -0.30 | -0.34 |
| EPS Diluted | -0.43 | -0.49 | -0.49 | -0.47 | -0.55 |
| Normalized Diluted EPS | -0.27 | -0.31 | -0.31 | -0.30 | -0.34 |
| Average Basic Shares Outstanding | 41.84M | 38.72M | 38.66M | 38.56M | 38.46M |
| Average Diluted Shares Outstanding | 41.84M | 38.72M | 38.66M | 38.56M | 38.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |